ViQi, Inc.

Startup

At ViQi we believe that imaging cells and tissues unlocks a vast untapped potential to improve and optimize the entire virus research and vaccine/antiviral discovery industry. Data analysis is the current bottleneck for this reality. To this goal, we have designed a builder for predictive AI assays that dramatically simplifies the assay automation process. Our assays follow a proprietary Phenotypically Targeted AI (PTA™) approach which automates and operationalizes predictive AI assay creation. With our innovative system, each tool is crafted to help our customers discover faster and more accurately, paving the way for groundbreaking advancements in image-based analysis.

ViQi developed an automated viral infectivity assay, AVIA™, which is an AI-based assay that uses machine learning and brightfield microscopy to detect phenotypic changes associated with viral infection prior to human visibility. Labs who have adopted AVIA are generally interested in the potential for increased capacity, and then are further impressed by its superior precision and numerous additional benefits such as requiring less training and no prior experience, rich image analysis of label-free cells, and more cost effective and sustainable than standard assays. Additionally, AVIA can offer advantages for BSL3/BSL4 viruses.